Changeflow GovPing Healthcare & Life Sciences Patent Application for Reducing DPP-4 Activity ...
Routine Notice Added Draft

Patent Application for Reducing DPP-4 Activity with Plants

Email

Summary

The USPTO has published a new patent application (US20260083813A1) detailing methods and compositions using plants like Dichrostachys glomerata or Cissus quadrangularis to reduce DPP-4 activity or levels in mammals. The application was filed on September 26, 2024.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

This document is a publication of a new patent application filed with the USPTO, specifically application US20260083813A1. The application describes methods and compositions utilizing naturally occurring plants, such as Dichrostachys glomerata or Cissus quadrangularis, to reduce Dipeptidyl Peptidase-4 (DPP-4) activity or levels in mammals. It also claims benefits such as increasing GLP-1 levels, reducing visceral fat, food intake, blood lipids, total cholesterol, and total glucose.

As this is a patent application, it does not impose immediate regulatory obligations or compliance deadlines on regulated entities. However, it signifies potential future developments in the pharmaceutical and dietary supplement industries related to these plant-based compounds for therapeutic or health-related purposes. Companies in the pharmaceutical and food manufacturing sectors may wish to monitor the progress of this patent application and related research.

Archived snapshot

Mar 27, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

METHODS AND COMPOSITIONS FOR REDUCING DPP-4 ACTIVITY OR LEVELS IN A MAMMAL USING NATURALLY OCCURING PLANTS AND SPICES

Application US20260083813A1 Kind: A1 Mar 26, 2026

Inventors

Shil Kothari, Julius Enyoug Oben

Abstract

Methods and compositions using Dichrostachys glomerata or Cissus quadrangularis separately to provide a variety of health benefits, including but not limited to, increase GLP-1 levels and reduce or decrease DPP-4 activity or levels, visceral fat, food intake, blood lipids, total cholesterol and total glucose, in a mammal. In one embodiment, a composition for reducing or decreasing DPP-4 activity or levels in a mammal is provided where the composition comprises an effective amount of Cissus quadrangularis provided as an oral dosage unit in the form of a pill, capsule, liquid, lozenge or tablet.

CPC Classifications

A61K 36/87 A61P 43/00 A61K 2236/33 A61K 2236/51

Filing Date

2024-09-26

Application No.

18898665

View original document →

Named provisions

Inventors Abstract CPC Classifications Filing Date Application No.

Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Instrument
Notice
Legal weight
Non-binding
Stage
Draft
Change scope
Minor
Document ID
US20260083813A1

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Drug Development Dietary Supplement Formulation
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Research & Development
Topics
Dietary Supplements Medical Research

Get alerts for this source

We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!